Published in Immunol Today on December 01, 1992
CNS immune privilege: hiding in plain sight. Immunol Rev (2006) 3.13
Regulation of learning and memory by meningeal immunity: a key role for IL-4. J Exp Med (2010) 2.40
Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann Neurol (2009) 2.15
Behavior of parasite-specific effector CD8+ T cells in the brain and visualization of a kinesis-associated system of reticular fibers. Immunity (2009) 1.84
Long-term persistence of activated cytotoxic T lymphocytes after viral infection of the central nervous system. J Exp Med (1998) 1.68
Inhibition of vesicular stomatitis virus infection by nitric oxide. J Virol (1995) 1.67
In situ tolerance within the central nervous system as a mechanism for preventing autoimmunity. J Exp Med (2000) 1.60
Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther (2007) 1.55
Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity. J Virol (1995) 1.52
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest (1997) 1.43
EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol (2009) 1.40
Temporal changes in cell marker expression and cellular infiltration in a controlled cortical impact model in adult male C57BL/6 mice. PLoS One (2012) 1.36
Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation (2008) 1.32
Cytokine induction during T-cell-mediated clearance of mouse hepatitis virus from neurons in vivo. J Virol (1994) 1.25
Inflammation and Spinal Cord Injury: Infiltrating Leukocytes as Determinants of Injury and Repair Processes. Clin Neurosci Res (2006) 1.24
Endogenous presentation of self myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice. J Clin Invest (1999) 1.23
Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.22
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun (2007) 1.20
Immunotherapy of malignant brain tumors. Immunol Rev (2008) 1.20
The immunogenicity of intracerebral virus infection depends on anatomical site. J Virol (1997) 1.19
Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis. Clin Dev Immunol (2011) 1.18
Neutrophil infiltration, glial reaction, and neurological disease in transgenic mice expressing the chemokine N51/KC in oligodendrocytes. J Clin Invest (1996) 1.13
Cytokines in the brain during viral infection: clues to HIV-associated dementia. J Clin Invest (1997) 1.12
Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol (2010) 1.10
Immune privilege of the CNS is not the consequence of limited antigen sampling. Sci Rep (2014) 1.09
Characterization of mouse hepatitis virus-specific cytotoxic T cells derived from the central nervous system of mice infected with the JHM strain. J Virol (1993) 1.09
T cell ignorance in mice to Borna disease virus can be overcome by peripheral expression of the viral nucleoprotein. Proc Natl Acad Sci U S A (1999) 1.08
Depletion of blood-borne macrophages does not reduce demyelination in mice infected with a neurotropic coronavirus. J Virol (1999) 1.07
Swift entry of myelin-specific T lymphocytes into the central nervous system in spontaneous autoimmune encephalomyelitis. J Immunol (2008) 1.06
Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res (2007) 1.06
Gene transfer into rat brain using adenoviral vectors. Curr Protoc Neurosci (2010) 1.05
Control of central nervous system viral persistence by neutralizing antibody. J Virol (2003) 1.05
Molecular and cellular neuroinflammatory status of mouse brain after systemic lipopolysaccharide challenge: importance of CCR2/CCL2 signaling. J Neuroinflammation (2014) 1.04
A special form of cerebral lacunae: expanding lacunae. J Neurol Neurosurg Psychiatry (1996) 0.98
Rett syndrome and other autism spectrum disorders--brain diseases of immune malfunction? Mol Psychiatry (2010) 0.97
Cerebrospinal fluid. J Neurol Neurosurg Psychiatry (1995) 0.94
Pseudorabies virus-induced leukocyte trafficking into the rat central nervous system. J Virol (1998) 0.93
Characterization of and functional antigen presentation by central nervous system mononuclear cells from mice infected with Theiler's murine encephalomyelitis virus. J Virol (1998) 0.93
Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res (2014) 0.92
Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier. Adv Drug Deliv Rev (2011) 0.91
Anatomical and cellular requirements for the activation and migration of virus-specific CD8+ T cells to the brain during Theiler's virus infection. J Virol (2005) 0.89
The movers and shapers in immune privilege of the CNS. Nat Immunol (2017) 0.88
Cytokine networks in glioma. Neurosurg Rev (2011) 0.88
Immune regulation of transgene expression in the brain: B cells regulate an early phase of elimination of transgene expression from adenoviral vectors. Viral Immunol (2006) 0.88
Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. J Neurol Neurosurg Psychiatry (1996) 0.87
Immunology of neurological gene therapy: how T cells modulate viral vector-mediated therapeutic transgene expression through immunological synapses. Neurotherapeutics (2007) 0.84
Vascular disruption and the role of angiogenic proteins after spinal cord injury. Transl Stroke Res (2011) 0.84
Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells. Childs Nerv Syst (2004) 0.83
Vascular, glial, and lymphatic immune gateways of the central nervous system. Acta Neuropathol (2016) 0.82
Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma. Neuro Oncol (2015) 0.82
Sustained TNF production by central nervous system infiltrating macrophages promotes progressive autoimmune encephalomyelitis. J Neuroinflammation (2016) 0.81
Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evid (2012) 0.81
Glial grafting for demyelinating disease. Philos Trans R Soc Lond B Biol Sci (2005) 0.81
Immunotherapy for malignant glioma. Surg Neurol Int (2015) 0.81
Research into the Physiology of Cerebrospinal Fluid Reaches a New Horizon: Intimate Exchange between Cerebrospinal Fluid and Interstitial Fluid May Contribute to Maintenance of Homeostasis in the Central Nervous System. Neurol Med Chir (Tokyo) (2016) 0.80
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? Front Oncol (2016) 0.80
Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen. Acta Neuropathol (2016) 0.79
Harnessing the immune system for neuroprotection: therapeutic vaccines for acute and chronic neurodegenerative disorders. Cell Mol Neurobiol (2001) 0.79
yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients. J Transl Med (2009) 0.79
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites. Front Oncol (2015) 0.79
Passage of intravenous immunoglobulin and interaction with the CNS. J Neurol Neurosurg Psychiatry (1994) 0.79
The Role of Cell-Penetrating Peptide and Transferrin on Enhanced Delivery of Drug to Brain. Int J Mol Sci (2016) 0.78
Cerebrospinal fluid outflow along lumbar nerves and possible relevance for pain research: case report and review. Croat Med J (2014) 0.77
CD4(+) T cells require either B cells or CD8(+) T cells to control spread and pathogenesis of a neurotropic infection. Virology (2016) 0.77
Impact of Human Immunodeficiency Virus in the Pathogenesis and Outcome of Patients with Glioblastoma Multiforme. Brain Tumor Res Treat (2016) 0.76
The blood brain barrier and the role of ratiometric molecular analysis in schizophrenia. Psychiatry (Edgmont) (2010) 0.75
B-Cell Depletion with CD20 Antibodies as New Approach in the Treatment of Inflammatory and Immunological Events Associated with Spinal Cord Injury. Neurotherapeutics (2016) 0.75
Tolerogenic effect of fiber tract injury: reduced EAE severity following entorhinal cortex lesion. Exp Brain Res (2006) 0.75
Adaptive immune response to viral infections in the central nervous system. Handb Clin Neurol (2014) 0.75
Embracing rejection: Immunologic trends in brain metastasis. Oncoimmunology (2016) 0.75
Fetal thymus graft enables recovery from age-related hearing loss and expansion of CD4-Positive T cells expressing IL-1 receptor type 2 and regulatory T Cells. Immun Ageing (2015) 0.75
The lymphatic vascular system of the mouse head. Cell Tissue Res (2016) 0.75
Aspects on the Physiological and Biochemical Foundations of Neurocritical Care. Front Neurol (2017) 0.75
Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathol (1992) 2.22
Immunoglobulin binding by mouse intestinal epithelial cell receptors. J Immunol (1976) 1.57
Intracellular transport and secretion of an immunoglobulin light chain. Biochemistry (1971) 1.36
Subcellular fractionation of mouse myeloma cells. Biochemistry (1971) 1.27
Role of cervical lymph nodes in the systemic humoral immune response to human serum albumin microinfused into rat cerebrospinal fluid. J Neuroimmunol (1989) 1.24
Biosynthetic units of an immunoglobulin heavy chain. Proc Natl Acad Sci U S A (1967) 1.18
Extracellular volume decreases while cell volume is maintained by ion uptake in rat brain during acute hypernatremia. J Physiol (1991) 1.10
Anti-striatal antibodies in Tourette syndrome cause neuronal dysfunction. J Neuroimmunol (2000) 1.05
Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation. J Neuroimmunol (1999) 1.00
IgG1 hypergammaglobulinaemia in chronic parasitic infections in mice: magnitude of the response in mice infected with various parasites. Aust J Exp Biol Med Sci (1979) 0.98
A charge difference between an intracellular and secreted mouse myeloma globulin. Biochem Biophys Res Commun (1966) 0.95
Schistosoma mansoni: resistance to reinfection in the rat. Exp Parasitol (1977) 0.94
IgG1 hypergammaglobulinaemia in chronic parasitic infections in mice: evidence that the response reflects chronicity of antigen exposure. Aust J Exp Biol Med Sci (1979) 0.91
Ovalbumin is more immunogenic when introduced into brain or cerebrospinal fluid than into extracerebral sites. J Neuroimmunol (1992) 0.90
Hemoglobin synthesis in a cell-free system. Biochemistry (1965) 0.89
Combination therapy of Schistosoma japonicum by tubercidin and nitrobenzylthioinosine 5'-monophosphate. Biochem Pharmacol (1985) 0.89
Normal cerebrospinal fluid suppresses the in vitro development of cytotoxic T cells: role of the brain microenvironment in CNS immune regulation. J Neuroimmunol (1998) 0.86
Evaluation of recombinant protein r140, a polypeptide segment of tegumental glycoprotein Sm25, as a defined antigen vaccine against Schistosoma mansoni. Parasite Immunol (1997) 0.85
Immunoprecipitation analysis of radiolabelled protein antigens biosynthesized in vitro by S. mansoni. I. Identification of antigens uniquely recognized by protective antibodies. J Immunol (1985) 0.84
Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity. J Immunol (1997) 0.82
Afferent and efferent arms of the humoral immune response to CSF-administered albumins in a rat model with normal blood-brain barrier permeability. J Neuroimmunol (1992) 0.81
Migration of Schistosoma mansoni in normal and passively immunized laboratory rats. Am J Trop Med Hyg (1986) 0.81
Antibody-induced changes in expression of an immunoglobulin surface antigen. Eur J Immunol (1973) 0.80
Completion of Schistosoma mansoni life cycle in thyroidectomized rats and effects of thyroid hormone replacement therapy. J Parasitol (1985) 0.80
Myelin basic protein infused into cerebrospinal fluid suppresses experimental autoimmune encephalomyelitis. J Neuroimmunol (1991) 0.80
Hierarchy of immune responses to antigen in the normal brain. Curr Top Microbiol Immunol (2002) 0.79
Schistosoma mansoni: cloning of antigen gene sequences in Escherichia coli. Exp Parasitol (1990) 0.79
I-STOD: a new standardization method for analysing indirect-ELISA results of a schistosomiasis field study. Parasitology (2008) 0.79
The effect of assay conditions on the recovery of schistosomula from the lungs of normal and resistant rats infected with Schistosoma mansoni. J Parasitol (1978) 0.79
Recovery of parasites at different stages of migration following infection of rats with Schistosoma mansoni. Parasitology (1983) 0.79
Effects of host endocrine gland removal on the permissive status of laboratory rodents to infection by Schistosoma mansoni. Int J Parasitol (1980) 0.79
Schistosoma mansoni: peripheral and tissue eosinophilia in infected rats. Exp Parasitol (1979) 0.78
A role for centrally-released vasopressin in brain ion and volume regulation: a hypothesis. Prog Brain Res (1992) 0.77
A study of Schistosoma mansoni transferred into permissive and nonpermissive hosts. Int J Parasitol (1977) 0.77
Pathways leading to expression of immunoglobulins. Transplant Rev (1973) 0.77
Cloning and sequence analysis of the Schistosoma mansoni membrane glycoprotein antigen gene GP22. Mol Biochem Parasitol (1991) 0.77
Schistosoma mansoni: evidence that 'non-permissiveness' in 129/Ola mice involves worm relocation and attrition in the lungs. Parasitology (1989) 0.77
The effect of inhibitors of protein synthesis on the reexpression of surface immunoglobulin following antigenic modulation. Cell (1978) 0.77
Schistosoma mansoni: two-dimensional gel electrophoretic analysis of antigens uniquely immunoreactive with protective rat serum. Exp Parasitol (1991) 0.76
Interleukin-12 as an adjuvant for an antischistosome vaccine consisting of adult worm antigens: protection of rats from cercarial challenge. Infect Immun (1999) 0.75
Scanning electron microscope observations on tegument maturation in Schistosoma mansoni grown in permissive and non-permissive hosts. Am J Trop Med Hyg (1978) 0.75
Intrahepatic synthese of immunoglobulin G in chronic liver disease. Ann Acad Med Singapore (1980) 0.75
Cellular subpopulations in the expression of IgG1. Cell Immunol (1979) 0.75
Immunoprecipitation of biosynthetically-labelled products in the identification of antigens of murine red cells infected with the protozoan parasite, Plasmodium berghei. Aust J Exp Biol Med Sci (1979) 0.75
Synthesis of an immunoglobulin light chain: pulse-labeling studies. Arch Biochem Biophys (1973) 0.75
Intrahepatic synthesis of immunoglobulin in liver disease. Liver (1982) 0.75
Induction of a protective immune response in rats by injection of live or killed S. mansoni worms. Parasite Immunol (1984) 0.75
Differential sensitivity of memory cell subpopulations to anti-immunoglobulin and complement. Eur J Immunol (1978) 0.75
Elevated cerebrospinal fluid IgA in humans and rats is not associated with secretory component. J Neuroimmunol (1993) 0.75
A study of the mode of action of hycanthone against Schistosoma mansoni in vivo and in vitro. Am J Trop Med Hyg (1980) 0.75
Application of cloning techniques to development of a synthetic vaccine against schistosomiasis. Vet Parasitol (1982) 0.75
Control of parasitic infections in nonpermissive hosts: applications to improvement of vaccine efficacy. Vet Parasitol (1982) 0.75
Effects of protective immune serum on the yields of parasites and pulmonary cell reactions in schistosome-infected rats. Am J Trop Med Hyg (1986) 0.75
The role of host hormones in controlling survival and development of Schistosoma mansoni. Pharmacol Ther (1981) 0.75
Limitations to schistosome growth and maturation in nonpermissive hosts. J Chem Ecol (1986) 0.75